{"data":{"trials":{"globalActiveTrials":21347,"byDisease":[{"id":"hematology","label":"Bleeding Disorders","activeTrials":147},{"id":"endocrinology","label":"Type 1 Diabetes","activeTrials":408},{"id":"cardiology","label":"Heart Disease","activeTrials":2520},{"id":"pulmonology","label":"Lung Disease","activeTrials":235},{"id":"oncology","label":"Cancer","activeTrials":5876},{"id":"ophthalmology","label":"Vision / Blindness","activeTrials":216},{"id":"obesity","label":"Obesity & Metabolic","activeTrials":1039},{"id":"hepatology","label":"Liver Disease","activeTrials":1563},{"id":"neurology","label":"Neurodegenerative Disease","activeTrials":691},{"id":"gastroenterology","label":"Inflammatory Bowel Disease","activeTrials":784},{"id":"nephrology","label":"Chronic Kidney Disease","activeTrials":478},{"id":"rheumatology","label":"Autoimmune & Rheumatic Disease","activeTrials":590},{"id":"dermatology","label":"Skin & Genetic Skin Disease","activeTrials":257},{"id":"psychiatry","label":"Psychiatric & Mood Disorders","activeTrials":767},{"id":"geromedicine","label":"Aging & Precision Geromedicine","activeTrials":726}],"source":"ClinicalTrials.gov","_freshness":{"stale":false,"available":true,"partial":false,"computedAt":"2026-09-27T22:54:37.677Z","note":"Live from ClinicalTrials.gov."},"message":"Right now, 21,347 clinical trials are running to cure human disease. The window is still open.","byRegistry":{"clinicaltrials_gov":63651,"isrctn":2369},"dedupMethod":"exact cross-registry identifier matching; probabilistic = review only","asOf":"2026-09-27T22:54:38.459Z","scopeNote":"globalActiveTrials is a live ClinicalTrials.gov figure only. See `world` for the deduplicated multi-registry view with per-registry attribution."},"world":{"scope":"world","asOf":"2026-09-27T22:54:38.459Z","sourceRecordCount":66020,"deduplicatedCanonicalTrialCount":65949,"activeTrialCount":13601,"crossRegistryTrialCount":56,"byRegistry":{"clinicaltrials_gov":63651,"isrctn":2369},"byDisease":[{"id":"endocrinology","label":"Type 1 Diabetes","activeTrials":711,"byRegistry":{"clinicaltrials_gov":572,"isrctn":142}},{"id":"hematology","label":"Bleeding Disorders","activeTrials":989,"byRegistry":{"clinicaltrials_gov":982,"isrctn":8}},{"id":"cardiology","label":"Heart Disease","activeTrials":1157,"byRegistry":{"clinicaltrials_gov":1120,"isrctn":41}},{"id":"oncology","label":"Cancer","activeTrials":1852,"byRegistry":{"clinicaltrials_gov":1671,"isrctn":184}},{"id":"pulmonology","label":"Lung Disease","activeTrials":746,"byRegistry":{"clinicaltrials_gov":703,"isrctn":44}},{"id":"ophthalmology","label":"Vision / Blindness","activeTrials":540,"byRegistry":{"clinicaltrials_gov":517,"isrctn":26}},{"id":"obesity","label":"Obesity & Metabolic","activeTrials":1086,"byRegistry":{"clinicaltrials_gov":979,"isrctn":111}},{"id":"hepatology","label":"Liver Disease","activeTrials":920,"byRegistry":{"clinicaltrials_gov":763,"isrctn":166}},{"id":"neurology","label":"Neurodegenerative Disease","activeTrials":1204,"byRegistry":{"clinicaltrials_gov":1140,"isrctn":67}},{"id":"gastroenterology","label":"Inflammatory Bowel Disease","activeTrials":858,"byRegistry":{"clinicaltrials_gov":807,"isrctn":54}},{"id":"nephrology","label":"Chronic Kidney Disease","activeTrials":923,"byRegistry":{"clinicaltrials_gov":816,"isrctn":110}},{"id":"rheumatology","label":"Autoimmune & Rheumatic Disease","activeTrials":850,"byRegistry":{"clinicaltrials_gov":768,"isrctn":83}},{"id":"dermatology","label":"Skin & Genetic Skin Disease","activeTrials":652,"byRegistry":{"clinicaltrials_gov":620,"isrctn":35}},{"id":"psychiatry","label":"Psychiatric & Mood Disorders","activeTrials":1087,"byRegistry":{"clinicaltrials_gov":916,"isrctn":173}},{"id":"geromedicine","label":"Aging & Precision Geromedicine","activeTrials":1257,"byRegistry":{"clinicaltrials_gov":1136,"isrctn":123}}],"sources":[{"registry":"clinicaltrials_gov","name":"ClinicalTrials.gov","license":"public-domain","api":"JSON (API v2, keyless)","baseUrl":"https://clinicaltrials.gov/api/v2/","records":63651,"lastSyncAt":"2026-09-27T04:33:59.824Z","contractTest":"pass","inProductionSync":true},{"registry":"isrctn","name":"ISRCTN","license":"public","api":"XML (public, keyless)","baseUrl":"https://www.isrctn.com/api/query/format/default","records":2369,"lastSyncAt":"2026-09-27T04:35:52.189Z","contractTest":"pass","inProductionSync":true}],"dedupMethod":"exact cross-registry identifier matching; probabilistic = review only","counting":"sourceRecordCount counts registry records; deduplicatedCanonicalTrialCount counts real-world trials after exact cross-registry identifier merging. The two are never added together."},"research":{"count":5,"source":"The Last Economy Wire cure-research index","newestPublishedAt":"2026-09-27T00:00:00.000Z","pagination":{"limit":5,"offset":0,"total":1991,"returned":5,"hasMore":true,"nextCursor":"bzo1","nextOffset":5},"articles":[{"title":"Sex-specific metabolic regulation by the Drosophila RNA-binding protein Nab2","url":"https://www.biorxiv.org/content/10.64898/2026.09.25.754360v1?rss=1","source":"biorxiv.org","publishedAt":"2026-09-27T00:00:00.000Z","domain":"VIRTUAL_CELL","significance":"Researchers (in a study led by the authors investigating the Drosophila ZC3H14 orthologue Nab2) report a female-specific increase in the insulin-like peptide mRNAs dilp2 and dilp5, linking the RNA-binding protein Nab2 to sex-differential regulation of neurometabolic signaling. In the broader AI-for-disease framing, this identifies a concrete regulatory “engineering node” (RBP–target mRNA control of metabolic circuitry) that models and inference systems can prioritize for mechanistic correction rather than generic association. From The Last Economy lens, the work suggests an intelligence-inversion target—modulating how molecular “instructions” reshape metabolic state—where small regulatory phase shifts in RNA processing can drive large downstream transitions relevant to disease phenotypes."},{"title":"Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis","url":"https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1?rss=1","source":"biorxiv.org","publishedAt":"2026-09-27T00:00:00.000Z","domain":"DRUG_DESIGN","significance":"Researchers announced evidence that inhibiting SARM1—an executioner of programmed axon loss and upregulated in MS tissue—can uncouple axonal degeneration from demyelination, offering a targeted neuroprotective intervention rather than only modulating inflammation. In the bigger picture of AI-driven disease curing, this reframes MS neurodegeneration as an engineerable control problem with an identifiable pathway node, where computationally discovered targets can drive a “phase transition” from ongoing axonal failure to stabilized neural circuits. Through The Last Economy lens (intelligence inversion), the strategy shifts therapeutic intelligence from suppressing symptoms of immune disorder to disabling the downstream intrinsic “failure mechanism,” converting disease from stochastic breakdown into a tractable systems-control objective."},{"title":"A hydrogen-producing mitochondrion in an anaerobic eukaryotrophic rhizarian","url":"https://www.biorxiv.org/content/10.64898/2026.09.23.753574v1?rss=1","source":"biorxiv.org","publishedAt":"2026-09-27T00:00:00.000Z","domain":"VIRTUAL_CELL","significance":"The study used single-cell transcriptomics, led by the authors of the report, to reconstruct how PCE SSF—an anaerobic eukaryote with mitochondrion-related organelles (MROs)—generates ATP and maintains cofactor recycling under low-oxygen conditions, identifying a hydrogen-producing mitochondrial system. In the broader AI-for-disease context, this is a concrete example of engineering-like biological problem solving—mapping alternate energy metabolism via interpretable molecular “design rules,” which is the kind of phase-transition-aware, system-level intelligence an ML pipeline could generalize to hypoxia-driven pathologies. From The Last Economy lens, it reframes “intelligence” as inversion of canonical mitochondrial function: instead of aerobic respiration, the organelle adapts by switching metabolic circuitry, offering a mechanistic template for how therapeutic interventions might target disease states at the transition between metabolic regimes."},{"title":"Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age","url":"https://www.biorxiv.org/content/10.64898/2026.09.24.754271v1?rss=1","source":"biorxiv.org","publishedAt":"2026-09-27T00:00:00.000Z","domain":"FUNDING","significance":"Researchers announced a new inducible mouse model enabling temporally confined mitochondrial mutagenesis, showing that mtDNA mutations introduced early in life (first ~2 months) are sufficient to later produce diverse age-related pathologies and that severity is tuned by tissue-specific mechanisms. In the AI-for-cure bigger picture, this pinpoints an actionable “engineering window” where intervening or modeling mitochondrial genome evolution could preempt disease trajectories rather than merely treating endpoints. From a The Last Economy lens, the work is an intelligence inversion of aging causality—fixing when the “mutation program” runs—and hints at a phase-transition-like shift from early genomic perturbation to irreversible organismal decline."},{"title":"A single-nucleus multi-omic atlas of gene regulation across 21 adult human tissues","url":"https://www.biorxiv.org/content/10.64898/2026.09.25.754561v1?rss=1","source":"biorxiv.org","publishedAt":"2026-09-27T00:00:00.000Z","domain":"VIRTUAL_CELL","significance":"Researchers announced a single-nucleus multi-omic atlas—generated by integrating 459,856 paired transcriptomic and chromatin-accessibility profiles across 21 adult human tissues (including paired measurements from 160,688 nuclei)—that maps lineage- and context-specific gene-regulatory programs for 9 lineages, 61 broad cell types, and 313 subclusters. In the bigger picture of AI curing disease, this creates the high-resolution regulatory “design space” needed to translate non-coding genetic risk into actionable cellular mechanisms, enabling model-driven intervention as intelligence inverts from reading disease phenotypes to engineering regulatory fixes. From The Last Economy lens, the work is a phase-transition step: it turns fragmented omics into an integrated engineering reference, making disease a tractable system-identification problem rather than an opaque biological outcome."}]},"stats":{"totalWireSignals":3983,"totalCureResearch":1991,"diseaseFrontiers":15,"languages":20}},"meta":{"api":"The Last Economy Wire - Hope Signal API","version":"1.0","schemaVersion":"2","correlationId":"req_RXFMqUMB9_OM","generatedAt":"2026-09-27T22:54:38.569Z","documentation":"https://negativeresistance.com/embed","license":"Free for any use. Attribution appreciated."},"notModified":false,"etag":"W/\"150b8b5de0a17e1a45506540c4b9b17bdf288274\""}